Analysis of Risk Factors for Low Molecular Weight Heparin Anticoagulant Bleeding in End-stage Renal Disease Patients with Atrial Fibrillation after Hemodialysis
ZHAO Liao-liao, CHANG Lu-yuan
Department of Nephrology, Yulin Second Hospital, Yulin Shaanxi 719000
Abstract：【Objective】To explore the risk factors of low molecular weight heparin anticoagulant bleeding in patients with end-stage renal disease (ESRD) with atrial fibrillation after hemodialysis treatment. 【Methods】A retrospective analysis of the clinical data of 400 ESRD patients with atrial fibrillation admitted to our hospital was performed. The incidence of low molecular weight heparin anticoagulant bleeding after hemodialysis in ESRD patients with atrial fibrillation was counted. Logistic regression analysis was used to analyze the multiple factors affecting low molecular weight heparin anticoagulant bleeding in patients with ESRD with atrial fibrillation after hemodialysis treatment. 【Results】The incidence of low-molecular-weight heparin anticoagulant bleeding events after hemodialysis in ESRD patients with atrial fibrillation was 7.40% (37/400). There were statistically significant differences between the bleeding group and the non-bleeding group in terms of age, drinking history, comorbid digestive tract disease, weekly dialysis time, platelet count, hypocalcemia, and spicy food eating habit(P<0.05). Logistic multivariate analysis showed that gastrointestinal diseases, weekly dialysis time, and hypocalcemia were independent influencing factors of low molecular weight heparin anticoagulant bleeding after hemodialysis in ESRD patients with atrial fibrillation (P<0.05). 【Conclusion】Gastrointestinal diseases, weekly dialysis time and hypocalcemia are risk factors for low-molecular-weight heparin anticoagulant bleeding in ESRD patients with atrial fibrillation after hemodialysis treatment.
[1] 王慧杰,孙帅,张虹. 心房颤动与慢性肾脏病的关系和治疗[J].中华老年心脑血管病杂志,2018,20(10):1102-1105.
[2] COBO G,LINDHOLM B,STENVINKEL P. Chronic inflammation in end-stage renal disease and dialysis[J].Nep Dial Transplant,2018,33(3):35-40.
[3] HU A,NIU J,WINKELMAYER W C. Oral anticoagulation in patients with end-stage kidney disease on dialysis and atrial fibrillation[J].Semin Nep,2018,38(6):618-628.
[4] 赖玮婧.慢性肾脏病评估及管理临床实践指南解读—从K/DOQI到KDIGO[J].中国实用内科杂志,2013,33(6):448-453.
[5] 杨延宗,孙源君. 新型抗凝药物循证证据进一步积累—欧洲心律学会关于非瓣膜病心房颤动患者应用新型抗凝药指南更新解读[J].中国循环杂志,2016,31(2):134-138.
[6] 马丽丽,许红梅. 无肝素抗凝与低分子肝素抗凝对有出血倾向的危重患者连续性血液净化影响的Meta分析[J].护士进修杂志,2015,30(23):2119-2124.
[7] OLIVERO J J. Continuous venous-venous-hemodialysis versus intermittent-hemodialysis in critically Ⅲ patients[J].Methodist Debakey Cardiovasc J,2018,14(2):153-155.
[8] YOUNG A M.Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)[J].J Clin Oncol,2018,36(20):2017-2023.
[9] PEMA A F,CAPOLONGO G,TREPICCIONE F,et al. COVID-19,low-molecular-weight heparin,and hemodialysis[J].Kidney Blood Press Res,2020,45(3):357-362.
[10] HINSLEY K.Low molecular weight heparin as an anticoagulation strategy for left-sided ablation procedures[J].Congenit Heart Dis,2018,13(2):222-225.
[11] LIN A,VAZQUEZ S R,JONES A E,et al. Description of anti-xa monitoring practices during low molecular weight heparin use[J].J Thromb Thrombolysis,2019,48(4):623-628.
[12] SUN W L,WANG N,XU Y. Impact of miR-302b on calcium-phosphorus metabolism and vascular calcification of rats with chronic renal failure by regulating BMP-2/Runx2/osterix signaling pathway[J].Arch Med Res,2018,49(3):164-171.
2022, Vol. 39 
